+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyaluronic Acid Market Size, Share & Trends Analysis Report by Application (Dermal Fillers, Osteoarthritis (Single Injection, Three Injection, Five Injection), Ophthalmic, Vesicoureteral Reflux), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 3450702
  • Report
  • February 2020
  • Region: Global
  • 150 pages
  • Grand View Research

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan
  • Ferring B.V.
  • Genzyme Corporation
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
  • Seikagaku Corporation
  • MORE
The global hyaluronic acid market size is expected to reach USD 16.6 billion by 2027, expanding at a CAGR of 8.1%. Factors such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers of this market.

The market is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with growing awareness about anti-aging products is fueling the growth. The efficacy and evident results of hyaluronic acid based dermal fillers are attracting this population base.

The global increase in population also results in an increased demand for antiaging cosmetic and aesthetic treatments. Owing to its distinctive viscoelastic and moisturizing properties coupled with lower toxicity levels, hyaluronic acid products are directly affected by growing demand for minimally invasive antiaging solutions. The minimal adverse effects, lower pain, shorter recovery time, and lesser postsurgical complications make minimally invasive surgeries significantly attractive.

Further key findings from the study suggest:
  • The osteoarthritis segment held the largest share in 2019. In 2013, more than 27 million people were suffering from osteoarthritis. Viscosupplements are gaining popularity as a cure in pain management. Use of hyaluronan as a treatment for osteoarthritis has been approved by the U.S. FDA in 1997 and has gained substantial market share
  • The rising obesity resulting in osteoarthritis and joint pain has increased the demand for hyaluronic acid injections as treatment. With the prevailing consumer trend, which favors convenience over higher costs, companies such as Genzyme (Sanofi-Aventis) and Zimmer have launched single-injection products. The 2014 FDA approval for single-injection treatment “MONOVISC” is expected to further fuel the growth of the single-injection product segment
  • Cosmetic surgeries are booming with approximately 14 million minimally invasive procedures performed every year. In 2013, hyaluronan-based facial fillers received FDA approval, which is used in corrective measures, anti-aging procedure, and filling fine lines. These dermal fillers constitute a large share in these procedures and witnessed 8% growth in the year 2014
  • Growing preference for short-treatment regimens, even though high priced, and growing prevalence of target diseases, such as osteoarthritis, are high impact rendering factors that can be attributed for the large share of this region. In 2019, the most lucrative applications of hyaluronic acid in the North American region were in the form of dermal fillers and viscosupplements for management of osteoarthritis
  • Hyaluronic acid market in Asia Pacific region is anticipated to emerge as the fastest growing region during the forecast period. The growing geriatric population in China and Japan provides a large customer base for anti-aging products and services. Increasing awareness about applications of hyaluronan and its efficacy fuels the demand. In addition, stabilizing economies leaves the middle-class population with surplus money to spend on these procedures
  • The industry is presently dominated by key participants such as F. Hoffmann-La Roche Ltd., Seikagaku Corporation, Galderma S.A, Sanofi (Genzyme), Anika Therapeutics Inc., Salix Pharmaceuticals, Zimmer Holdings Inc., Allergan Inc., Ferring Pharmaceuticals, Inc., and Smith & Nephew Plc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan
  • Ferring B.V.
  • Genzyme Corporation
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
  • Seikagaku Corporation
  • MORE
Chapter 1 Research Objective
1.1 Objective - 1
1.2 Objective - 2
1.3 Objective - 3
1.4 Objective - 4

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Application
2.2.2 Region
2.3 Competitive Insights
2.4 Hyaluronic Acid Market Snapshot

Chapter 3 Hyaluronic Acid Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Market Segmentation
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market influencer analysis
3.4 Penetration and Growth Prospect Mapping
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Increasing geriatric population and prevalence of osteoarthritis
3.5.1.2 Growing demand for antiaging solutions and minimally invasive aesthetic treatments
3.5.1.3 Growing application in regenerative medicine and tissue engineering
3.5.1.4 Market approval and launch of new products
3.5.2 Market restraint analysis
3.5.2.1 High cost and side effects associated with hyaluronic acid cycles
3.6 Business Environment Analysis Tools
3.6.1 Industry analysis - Porter’s
3.6.1.1 Competitive rivalry
3.6.1.2 Threat of new entrants
3.6.1.3 Bargaining power of buyers
3.6.1.4 Bargaining power of suppliers
3.6.1.5 Threat of substitutes
3.6.2 PESTEL analysis
3.6.2.1 Political landscape
3.6.2.2 Economic and social landscape
3.6.2.3 Technology landscape
3.7 Major Deals & Strategic Alliances Analysis
3.7.1 Joint ventures
3.7.2 Mergers & acquisitions

Chapter 4 Hyaluronic Acid Market: Application Estimates & Trend Analysis
4.1 Segment Dashboard
4.2 Hyaluronic Acid Market: Application Movement Analysis, USD Million, 2019 & 2027
4.2.1 Dermal fillers
4.2.1.1 Dermal fillers market, 2016 - 2027 (USD Million)
4.2.2 Osteoarthritis
4.2.2.1 Osteoarthritis market, 2016 - 2027 (USD Million)
4.2.2.1.1 Single injection
4.2.2.1.1.1 Single injection market, 2016 - 2027 (USD Million)
4.2.2.1.2 Three injection
4.2.2.1.2.1 Three injection market, 2016 - 2027 (USD Million)
4.2.2.1.3 Five injection
4.2.2.1.3.1 Five injection market, 2016 - 2027 (USD Million)
4.2.3 Ophthalmic
4.2.3.1 Ophthalmic market, 2016 - 2027 (USD Million)
4.2.4 Vesicoureteral reflux
4.2.4.1 Vesicoureteral market, 2016 - 2027 (USD Million)

Chapter 5 Hyaluronic Acid Market: Regional Estimates & Trend Analysis, By Application
5.1 Regional Market Share Analysis, 2019 & 2027
5.2 Regional Market Dashboard
5.3 Regional Market Snapshot (Countries)
5.4 North America
5.4.1 North America hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.4.2 U.S.
5.4.2.1 U.S. hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.4.3 Canada
5.4.3.1 Canada hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5 Europe
5.5.1 Europe hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5.2 Germany
5.5.2.1 Germany hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5.3 U.K.
5.5.3.1 U.K. hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5.4 France
5.5.4.1 France hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5.5 Italy
5.5.5.1 Italy hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.5.6 Spain
5.5.6.1 Spain hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.6 Asia Pacific
5.6.1 Asia Pacific hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.6.2 Japan
5.6.2.1 Japan hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.6.3 China
5.6.3.1 China hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.6.4 India
5.6.4.1 India hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.7 Latin America
5.7.1 Latin America hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.7.2 Brazil
5.7.2.1 Brazil hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.7.3 Mexico
5.7.3.1 Mexico hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.8 Middle East & Africa
5.8.1 Middle East & Africa hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)
5.8.2 South Africa
5.8.2.1 South Africa hyaluronic acid market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 6 Reimbursement Outlook
6.1 Reimbursement By Product
6.1.1 Gel-one
6.1.2 EUFLEXXA
6.1.3 Synvisc-One
6.1.4 Supartz
6.1.5 Hyalgan
6.1.6 Monovisc
6.1.7 Orthovisc
6.1.8 Others
6.2 Reimbursement By Region
6.2.1 Canada
6.2.2 China
6.2.3 Japan
6.2.4 India
6.2.5 Brazil
6.2.6 South Africa
6.2.7 Europe
6.2.7.1 U.K.
6.2.7.2 Germany
6.2.7.3 France
6.2.7.4 Italy
6.2.7.5 Spain

Chapter 7 Competitive Landscape
7.1 Strategic Framework/ Competition Categorization (Key Innovators, Market Leaders, Emerging Players
7.2 Vendor Landscape
7.2.1 List of key distributors and channel partners
7.2.2 Strategy mapping
7.2.2.1 Partnerships
7.2.2.2 Launch of new products
7.2.2.3 Merger & acquisition
7.2.2.4 Geographical expansion
7.2.2.5 Marketing & promotions
7.2.3 Company market position analysis (market presence, geographic presence, product portfolio, strategic initiatives)
7.3 Company Profiles
7.3.1 Allergan
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.1.5 SWOT analysis
7.3.1.6 Strategic initiatives
7.3.2 Sanofi
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3.5 SWOT analysis
7.3.4.6 Strategic initiatives
7.3.3 Genzyme Corporation
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.3.5 SWOT analysis
7.3.3.6 Strategic initiatives
7.3.4 Salix Pharmaceuticals, Inc.
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.4.5 SWOT analysis
7.3.4.6 Strategic initiatives
7.3.5 Seikagaku Corporation
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.5.5 SWOT analysis
7.3.5.6 Strategic initiatives
7.3.6 F. Hoffmann-La Roche AG
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.6.5 SWOT analysis
7.3.6.6 Strategic initiatives
7.3.7 Galderma S.A.
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.7.5 SWOT analysis
7.3.7.6 Strategic initiatives
7.3.8 Zimmer Biomet
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.8.5 SWOT analysis
7.3.8.6 Strategic initiatives
7.3.9 Smith & Nephew Plc
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
7.3.9.5 SWOT analysis
7.3.9.6 Strategic initiatives
7.3.10 Ferring B.V.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives
7.3.10.5 SWOT analysis
7.3.10.6 Strategic initiatives
7.3.11 Lifecore Biomedical, LLC
7.3.11.1 Company overview
7.3.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic initiatives
7.4.11.5 SWOT analysis
7.4.11.6 Strategic initiatives
7.3.12 HTL Biotechnology
7.3.12.1 Company overview
7.3.12.2 Financial performance
7.4.12.3 Product benchmarking
7.4.12.4 Strategic initiatives
7.4.12.5 SWOT analysis
7.4.12.6 Strategic initiatives
7.3.13 Shiseido Company, Limited
7.3.13.1 Company overview
7.3.13.2 Financial performance
7.4.13.3 Product benchmarking
7.4.13.4 Strategic initiatives
7.4.13.5 SWOT analysis
7.4.13.6 Strategic initiatives
7.3.14 Bloomage Freda Biopharm Co. Ltd.
7.3.14.1 Company overview
7.3.14.2 Financial performance
7.4.14.3 Product benchmarking
7.4.14.4 Strategic initiatives
7.4.14.5 SWOT analysis
7.4.14.6 Strategic initiatives
7.3.15 LG Life Sciences Ltd
7.3.15.1 Company overview
7.3.15.2 Financial performance
7.4.15.3 Product benchmarking
7.4.15.4 Strategic initiatives
7.4.15.5 SWOT analysis
7.4.15.6 Strategic initiatives
7.3.16 Maruha Nichiro, Inc.
7.3.16.1 Company overview
7.3.16.2 Financial performance
7.4.16.3 Product benchmarking
7.4.16.4 Strategic initiatives
7.4.16.5 SWOT analysis
7.4.16.6 Strategic initiatives

Chapter 8 Recommendations

Chapter 9 Research Methodology & Scope
9.1 Research Methodology
9.1.1 Information procurement
9.1.1.1 Purchased database:
9.1.1.2 Internal database
9.1.2 Primary research:
9.2 Research Scope And Assumptions
9.3 List To Data Sources

Chapter 10 Report FAQs
10.1 How Do I Trust Your Report Quality/Data Accuracy?
10.2 My Research Requirement Is Very Specific; Can I Customize This Report?
10.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
10.4 How Do You Arrive At These Market Numbers?
10.5 Who Are Your Clients?
10.6 How Will I Receive This Report?

Chapter 11 Appendix

Chapter 12 Compass - Cloud Based Report Delivery Platform

Chapter 13 Related Reports


*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
  • Allergan
  • Sanofi
  • Genzyme Corporation
  • Salix Pharmaceuticals, Inc.
  • Seikagaku Corporation
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • Zimmer Biomet
  • Smith & Nephew Plc
  • Ferring B.V.
  • Lifecore Biomedical, LLC
  • HTL Biotechnology
  • Shiseido Company, Limited
  • Bloomage Freda Biopharm Co. Ltd.
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll